Contact lens composition and contact lens product

Abstract

The present disclosure provides contact lens compositions.SOLUTION: The contact lens composition comprises an antibacterial agent which is nanosilver and a dispersant which is a polymeric dispersant. By using the polymer dispersant, the nanosilver can be well mixed with other components, and a specific ratio of the nanosilver to the dispersant can be designed under a specific condition, so that the dispersant has an excellent nanosilver encapsulation effect, which can prevent the nanosilver from aggregation and improve the dispersion uniformity of the nanosilver, thereby achieving an excellent antibacterial effect.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present disclosure relates to a contact lens composition and a contact lens product, and in particular to a contact lens composition and a contact lens product that have excellent antibacterial effects and moisturizing properties. [Background technology]

[0002] When contact lenses are worn for long periods of time, they are prone to friction with the eye, damaging the cornea and increasing the risk of bacterial infection. Reused contact lenses are more likely to carry bacteria, increasing the likelihood of causing redness, swelling, fever, pain, and inflammation in the wearer's eye. To avoid bacterial eye infection, antibacterial agents can be added to contact lens components. Nanosilver can maintain its antibacterial effect for a long period of time, but its high agglomeration tendency prevents it from dispersing evenly within the contact lens, further reducing its antibacterial effect. Therefore, in order to fully utilize the antibacterial effect of nanosilver, it is necessary to develop a more effective nanosilver dispersion technology. Summary of the Invention [Problem to be solved by the invention]

[0003] The present disclosure provides a contact lens composition and a contact lens product, which, by designing a specific ratio of nanosilver and dispersant, allows the dispersant to have an excellent nanosilver encapsulation effect, prevents the aggregation of nanosilver, contributes to improving the uniformity of the dispersion of nanosilver, and has excellent antibacterial effect. [Means for solving the problem]

[0004] According to one embodiment of the present disclosure, there is provided a contact lens composition comprising an antimicrobial agent that is nanosilver and a dispersant that is a polymeric dispersant, where Pag is the proportion of nanosilver in the contact lens composition, Pd is the proportion of dispersant in the contact lens composition, and MWd is the molecular weight of the dispersant, and the conditions Pag / Pd≦0.001 and 100,000 g / mol≦MWd are satisfied.

[0005] According to another embodiment of the present invention, there is provided a contact lens product comprising the contact lens composition described in the preceding paragraph and a buffer solution in which the contact lens composition is immersed.

[0006] According to another embodiment of the present invention, there is provided a contact lens composition comprising an antimicrobial agent that is nanosilver, a humectant that is a glucan, and a dispersant that is a polymeric dispersant, where MWd is the molecular weight of the dispersant, and the condition 300,000 g / mol≦MWd is satisfied.

[0007] According to another embodiment of the present invention, there is provided a contact lens product comprising the contact lens composition described in the preceding paragraph and a buffer solution in which the contact lens composition is immersed. DETAILED DESCRIPTION OF THE INVENTION

[0008] According to the present disclosure, a contact lens composition and a contact lens product are provided. By designing a specific ratio of nanosilver to dispersant, the dispersant has an excellent nanosilver encapsulation effect, preventing nanosilver aggregation and thereby contributing to improved dispersion uniformity of the nanosilver. Furthermore, the use of a polymer dispersant allows for good mixing of the nanosilver with other components. Since the larger the molecular weight of the dispersant, the better the dispersion durability, adding a dispersant with a specific molecular weight contributes to improving the dispersion durability of the dispersant for the nanosilver. Furthermore, adding glucan to the contact lens composition of the present disclosure can improve the moisturizing ability of the contact lens composition, contributing to improved comfort for the user.

[0009] According to one embodiment of one aspect of the present disclosure, a contact lens composition is provided, comprising an antimicrobial agent and a dispersant. The antimicrobial agent is nanosilver. The dispersant is a polymeric dispersant. Where the proportion of nanosilver in the contact lens composition is Pag, the proportion of dispersant in the contact lens composition is Pd, and the molecular weight of the dispersant is MWd, the following conditions are satisfied: Pag / Pd≦0.001, and 100,000 g / mol≦MWd. By designing a specific ratio of nanosilver to dispersant, the dispersant can have an excellent encapsulation effect on the nanosilver, preventing aggregation of the nanosilver and thereby improving the uniformity of the nanosilver dispersion. Furthermore, the use of a polymeric dispersant allows for good mixing of the nanosilver with other components. Since the larger the molecular weight of the dispersant, the better the dispersion durability, the addition of a dispersant with a specific molecular weight contributes to improving the dispersion duration of the dispersant for the nanosilver.

[0010] According to another embodiment of one aspect of the present disclosure, there is provided a contact lens composition comprising an antibacterial agent, a humectant, and a dispersant. The antibacterial agent is nanosilver. The humectant is glucan. The dispersant is a polymeric dispersant. When the molecular weight of the dispersant is MWd, the condition 300,000 g / mol≦MWd is satisfied. Thus, the addition of glucan can improve the humectant ability of the contact lens composition, contributing to improved comfort for the user. Furthermore, the use of a polymeric dispersant can facilitate good mixing of nanosilver with other components. Since the larger the molecular weight of the dispersant, the better the dispersion sustainability, the addition of a dispersant with a specific molecular weight contributes to improving the dispersion sustainability of the dispersant relative to the nanosilver.

[0011] When the molecular weight of the dispersant is MWd, it may satisfy the condition of 1000000 g / mol ≤ MWd. Since the higher the molecular weight of the dispersant, the better the dispersion persistence, adding a dispersant with a specific molecular weight contributes to improving the dispersion duration of silver nanoparticles. Or, it may satisfy the condition of 500000 g / mol ≤ MWd. Or, it may satisfy the condition of 800000 g / mol ≤ MWd. Or, it may satisfy the condition of 1000000 g / mol ≤ MWd ≤ 1500000 g / mol. Or, it may satisfy the condition of 1200000 g / mol ≤ MWd ≤ 1300000 g / mol.

[0012] The polymeric dispersant may be polyvinylpyrrolidone. Using polyvinylpyrrolidone as the dispersant, the excellent dispersing ability of polyvinylpyrrolidone can achieve an optimal mixing of silver nanoparticles and other components.

[0013] When the proportion of silver nanoparticles in the contact lens composition is Pag and the proportion of the dispersant in the contact lens composition is Pd, it may satisfy the condition of 0.0002 ≤ Pag / Pd ≤ 0.0007. By designing a specific ratio of silver nanoparticles and the dispersant, the dispersant has an excellent silver nanoparticle encapsulation effect, preventing the aggregation of silver nanoparticles, thereby contributing to improving the dispersion uniformity of silver nanoparticles. Or, it may satisfy the condition of Pag / Pd ≤ 0.0008. Or, it may satisfy the condition of 0 < Pag / Pd ≤ 0.0008. Or, it may satisfy the condition of 0.0003 ≤ Pag / Pd ≤ 0.0006. Or, it may satisfy the condition of 0.0004 ≤ Pag / Pd ≤ 0.0005.

[0014] When the proportion of nanosilver in a contact lens composition is designated as Pag, the proportion may satisfy the condition 0.0003%≦Pag. Adding a specific concentration of nanosilver imparts an antibacterial effect to the contact lens composition, helping to prevent bacterial contamination of the contact lens composition. Alternatively, the proportion may satisfy the condition 0.00025%≦Pag. Alternatively, the proportion may satisfy the condition 0.00033%≦Pag≦0.01%. Alternatively, the proportion may satisfy the condition 0.00035%≦Pag≦0.001%. Alternatively, the proportion may satisfy the condition 0.00038%≦Pag≦0.0008%. Alternatively, the proportion may satisfy the condition 0.0004%≦Pag≦0.0005%. Alternatively, the proportion may satisfy the condition 0.00042%≦Pag≦0.00048%.

[0015] When the proportion of the dispersant in the contact lens composition is Pd, it may satisfy the condition 0.3%≦Pd≦3.0%. Adding a specific concentration of dispersant allows the nanosilver to be uniformly dispersed in the contact lens composition, contributing to improved transparency of the contact lens composition and distributing the antibacterial effect throughout the contact lens composition. Alternatively, it may satisfy the condition 0.1%≦Pd. Alternatively, it may satisfy the condition 0.2%≦Pd≦5.0%. Alternatively, it may satisfy the condition 0.5%≦Pd≦2.0%. Alternatively, it may satisfy the condition 0.8%≦Pd≦1.5%.

[0016] When the particle size of the nanosilver is Dag, the particle size may satisfy the condition Dag≦100 nm. By limiting the particle size of the nanosilver, the antibacterial effect of the nanosilver can be improved, further contributing to preventing bacterial contamination of the contact lens composition. Alternatively, the particle size may satisfy the condition Dag≦200 nm. Alternatively, the particle size may satisfy the condition Dag≦150 nm. Alternatively, the particle size may satisfy the condition 60 nm≦Dag≦90 nm. Alternatively, the particle size may satisfy the condition 70 nm≦Dag≦80 nm.

[0017] When the particle size of the contact lens composition is Dc, it may satisfy the condition of 100 nm ≤ Dc ≤ 300 nm. By restricting the particle size of the contact lens composition, the haze of the contact lens composition can be reduced, contributing to further improvement in the transparency of the contact lens composition. Or, it may satisfy the condition of Dc ≤ 500 nm. Or, it may satisfy the condition of Dc ≤ 400 nm. Or, it may satisfy the condition of 150 nm ≤ Dc ≤ 200 nm. Or, it may satisfy the condition of 170 nm ≤ Dc ≤ 190 nm.

[0018] When the proportion of the humectant in the contact lens composition is Pm, it may satisfy the condition of 0.5% ≤ Pm ≤ 2.5%. By designing a specific proportion of the humectant in the contact lens composition, it contributes to achieving an optimal moisturizing effect of the contact lens composition. Or, it may satisfy the condition of 0% < Pm ≤ 5.0%. Or, it may satisfy the condition of 0.1% ≤ Pm ≤ 3.0%. Or, it may satisfy the condition of 1.0% ≤ Pm ≤ 2.0%. Or, it may satisfy the condition of 1.3% ≤ Pm ≤ 1.8%. Or, it may satisfy the condition of 1.4% ≤ Pm ≤ 1.6%.

[0019] When the K value of the dispersant is Kd, it may satisfy the condition of 50 ≤ Kd. By satisfying the K value of the dispersant, the dispersing ability of the dispersant can be improved, contributing to further improvement in the dispersion uniformity of silver nanoparticles. Or, it may satisfy the condition of 30 ≤ Kd. Or, it may satisfy the condition of 20 ≤ Kd. Or, it may satisfy the condition of 70 ≤ Kd. Or, it may satisfy the condition of 80 ≤ Kd ≤ 100. Or, it may satisfy the condition of 85 ≤ Kd ≤ 95.

[0020] When the average transmittance of the contact lens composition in the 400-700 nm range is defined as T4070, the contact lens composition may satisfy the condition 90%≦T4070. Limiting the average transmittance of the contact lens composition in the 400-700 nm range increases the transmittance of visible light, thereby contributing to preventing the user's line of sight from being obstructed. Alternatively, the contact lens composition may satisfy the condition 85%≦T4070. Alternatively, the contact lens composition may satisfy the condition 88%≦T4070. Alternatively, the contact lens composition may satisfy the condition 92%≦T4070. Alternatively, the contact lens composition may satisfy the condition 93%≦T4070≦100%.

[0021] The contact lens composition described herein may be a contact lens formulation solution before curing or a contact lens after curing. The curing may be photocuring or heat curing.

[0022] The components of the contact lens composition described in this disclosure include internal components and surface components of the contact lens composition. The internal components of the contact lens composition are those that use the components of the contact lens composition as materials. The surface components of the contact lens composition are those that are bonded or attached to the surface of the contact lens composition by methods such as coating or soaking. The components of the contact lens composition may include at least one, at least two, at least three, or at least four antimicrobial agents; the components of the contact lens composition may include at least one, at least two, at least three, or at least four dispersing agents; the components of the contact lens composition may include at least one, at least two, at least three, or at least four humectants; the components of the contact lens composition may include at least one, at least two, at least three, or at least four adjuvants; the components of the contact lens composition may include at least one, at least two, at least three, or at least four antioxidants; the components of the contact lens composition may include at least one, at least two, at least three, or at least four myopia progression retarding drugs; the components of the contact lens composition may include at least one, at least two, at least three, or at least four The contact lens composition components may include at least one, at least two, at least three, or at least four surfactants; the contact lens composition components may include at least one, at least two, at least three, or at least four cooling agents; the contact lens composition components may include at least one, at least two, at least three, or at least four eye-protecting ingredients; the contact lens composition components may include at least one, at least two, at least three, or at least four buffering agents; the contact lens composition components may include at least one, at least two, at least three, or at least four chelating agents; the contact lens composition components may include at least one, at least two, at least three, or at least four monomers; the contact lens composition components may include at least one, at least two, at least three, or at least four initiators; the contact lens composition components may include at least one,The contact lens composition may include at least two, at least three, or at least four crosslinking agents; the contact lens composition may include at least one, at least two, at least three, or at least four diluents; the contact lens composition may include at least one, at least two, at least three, or at least four ultraviolet light absorbing agents or blue light absorbing agents; and the contact lens composition may include at least one, at least two, at least three, or at least four dyes.

[0023] The percentage of each component in the contact lens composition described in this disclosure is calculated in weight percent, and when the contact lens composition is a contact lens, the contact lens composition must be completely dehydrated.

[0024] The antibacterial agent described in this disclosure is nanosilver, silver ions (Ag + ), benzoic acid, sodium nitrite, calcium propionate, boric acid, sodium borate, methylparaben, dimethylol dimethyl hydantoin (DMDMH), poly(hexamethylenebiguanide) (PHMB), and salts thereof. The nanosilver mentioned above is silver atoms with a particle diameter of less than 1000 nanometers.

[0025] The particle sizes described in this disclosure are Z-average results obtained using a dynamic light scattering particle size analyzer, and the formula is Dz=ΣSi / Σ(Si / Di), where Dz is the calculated particle diameter (the nanosilver particle size Dag and the contact lens composition particle size Dc described in this disclosure may be substituted), Si is the scattering intensity of a single particle, and Di is the diameter of a single particle.

[0026] The dispersant described in the present disclosure may include a cationic dispersant, an anionic dispersant, a nonionic dispersant, an amphoteric dispersant, an electrically neutral dispersant, a polymeric dispersant, or a radical dispersant. The cationic dispersant may include an amine salt, a quaternary amine salt, or a pyridinium salt. The anionic dispersant may include sodium oleate (C 17 H 33 The nonionic dispersant may include ethylene glycol or polyol. The amphoteric dispersant may include phosphate ester salt. The electrically neutral dispersant may include N-oleyl oleic acid amide (C 18 H 35 NH3OOCC 17 H 33 The polymer dispersant is a polymer dispersant, and may include polyvinylpyrrolidone (PVP), Hypermer B246, polycaprolactone polyol-polyethyleneimine block copolymer, acrylate polymer, polyurethane, polyester, and the like.

[0027] The molecular weight of the dispersant described in this disclosure is the weight average molecular weight, and the formula for the weight average molecular weight is Mw = (ΣNiMi 2 ) / (ΣNiMi), where Mw is the weight average molecular weight (which may be substituted with the molecular weight MWd of a dispersant described in this disclosure), Ni is the number of molecules of the corresponding molecular weight, and Mi is the molecular weight of a single molecule.

[0028] The K value of the dispersants described in this disclosure is an indicator of average molecular size based on relative viscosity and solubility. The K value is calculated using the Fikentscher equation, which is K = {[300C log η + (C + 1.5 log η)} 2 ] 1 / 2 +1.5logη-C} / (0.15C+0.003C 2 ), η is the relative viscosity, and C is the number of grams of solute dissolved in 100 ml of solution.

[0029] The moisturizer disclosed in the present disclosure may include glucan, polyethylene glycol 40 hydrogenated castor oil (PEG 40 Castor Oil), polyethylene glycol-400 (PEG 400), glycerol, allantoin, hyaluronic acid, ceramide, cholesterol, sea buckthorn oil, polyglutamic acid (γ-PGA), trehalose, alginic acid, hydroxypropyl methylcellulose (HPMC), 2-methacryloyloxyethyl phosphorylcholine (MPC), and salts thereof.

[0030] The adjuvants disclosed in the present disclosure may include antibiotics, bacteriostatic agents, antiviral agents, antifungal drugs, antiallergic agents, apomorphine, bromocriptine, dopamine receptor agonists, levodopa, quinpirole, steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), surfactants, miotics, enzyme inhibitors, anesthetics, vasoconstrictors, nutrients, and the like.

[0031] Antioxidants disclosed in the present disclosure may include vitamin A, vitamin C, vitamin D, vitamin E, uric acid, carotenoids, carotene, lutein, flavonoids, resveratrol, selenomethionine, oxidized or reduced coenzyme Q10, glutathione, thioctic acid, dibutylhydroxytoluene (BHT), butylhydroxyanisole (BHA), propyl gallate (PG), tert-butylhydroquinone (TBHQ), and salts thereof.

[0032] The myopia progression inhibitor disclosed in the present disclosure has the effect of inhibiting, mitigating, slowing down, or preventing the progression of myopia. Examples of myopia progression inhibitors include cycloplegics, eye drops that dilate the pupil (mydriatics), selective / non-selective muscarinic receptor antagonists, and the like, such as atropine ((3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yltropate), atropine sulfate, cyclopentolate (2-(Dimethylamino)ethyl(1-hydroxycyclopentyl)(phenyl)acetate), and cyclopentolate hydrochloride. HCl), Eucatropine (1,2,2,6-Tetramethyl-4-piperidinylhydroxy(phenyl)acetate), Homatropine ((3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-ylhydroxy(phenyl)acetate), Nuvenzepine, Fenefrine Hydrochloride HCl), pirenzepine, raceanisodamine, rispenzepine, scopolamine ((1R,2R,4S,5S,7s)-9-Methyl-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl(2S)-3-hydroxy-2-phenylpropanoate), scopolamine hydrobromide (scopolamine HBr), telenzepine, tropicamide (N-Ethyl-3-hydroxy-2-phenyl-N-(4-pyridinylmethyl)propanamide), and their salts.

[0033] Surfactants disclosed in the present disclosure may include poloxamer 407 (KP407), sodium dodecyl sulfate (SDS), cetyltrimethylammonium bromide (CTAB), stearyl trimethyl ammonium chloride (STAC), potassium stearate, gum arabic, sodium alginate, and salts thereof.

[0034] The cooling agent disclosed in the present disclosure has the effect of providing a cooling sensation to the affected area. Examples of the cooling agent include menthol, 2-Isopropyl-N,2,3-trimethylbutyramide (WS-23), N-Ethyl-p-menthane-3-carboxamide (WS-3), and ethyl 3-(p-menthane-3-carboxamide) acetate. 3-(p-menthane-3-carboxamido)acetate (WS-5), (1R,2S,5R)-N-(4-Methoxyphenyl)-p-menthanecarboxamide (WS-12), N-Ethyl-2,2-diisopropylbutanamide (WS-27), N-(1,1-Dimethyl-2-hydroxyethyl)-2,2-diethylbutanamide (WS-116), and salts thereof.

[0035] The eye protection ingredients disclosed in the present disclosure may include vitamin A, vitamin B, lutein, omega-3 fatty acids, anthocyanins, astaxanthin, carotene, blueberry extract, lecithin, or combinations thereof.

[0036] The buffering agents disclosed in the present disclosure may include buffer salts such as citrate, acetate, phosphate, borate, sulfate, carbonate, nitrate, chloride, or a combination of the above salts, and the cations of the buffer salts may include sodium, potassium, magnesium, calcium. The buffers used were N-tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid (TAPS), N,N-di(2-hydroxyethyl)glycine (Bicine), tris(hydroxymethyl)aminomethane (Tris), tricine, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid hemisodium salt (HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES, N-Tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid), 3-(N-morpholino)propanesulfonic acid (MOPS, 3-Morpholinopropanesulfonic acid), and piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES, 1,4-Piperazinediethanesulfonic acid). acid), cacodylate, 2-morpholinoethanesulphonic acid (MES), and salts thereof.

[0037] Chelating agents disclosed in the present disclosure may include ethylenediamine (en), 2,2'-bipyridyl (bipy), 1,10-phenanthroline (phen), oxalate (oxalic acid), ethylenediaminetetraacetic acid (EDTA), 1,2-bis(dimethylarsino)benzene (diars), and salts thereof.

[0038] The term "monomer" as used herein refers to a component that provides structural support in a contact lens composition and may be a hydrogel monomer or a silicone hydrogel monomer. Hydrogel monomers may include 2-hydroxyethyl methacrylate (HEMA), methacrylic acid (MAA), glycerol monomethacrylate (GMA), N-vinyl-2-pyrrolidinone (NVP), methyl methacrylate (MMA), N,N-dimethylacrylamide (DMAA), and the like. Silicone hydrogel monomers may include 2-hydroxyethyl methacrylate, glycerol monomethacrylate, methacrylic acid, 3-methacryloyloxypropyltris(trimethylsilyloxy)silane, N-vinyl-2-pyrrolidinone, N,N-dimethyl acrylamide, 3-(3-methacryloxy-2-hydroxypropoxy)propylbis(trimethylsiloxy)methylsilane, or (3-acryloxy-2-hydroxypropoxypropyl)terminated polydimethylsiloxane.

[0039] The initiator disclosed in the present disclosure may be 2-hydroxy-2-methyl-propiophenone or phenylbis(2,4,6-trimethylbenzoyl)phosphine oxide.

[0040] The crosslinking agent disclosed in the present disclosure may be ethylene glycol dimethacrylate (EGDMA) or 1,1,1-trimethylol propane trimethacrylate (TMPTA).

[0041] The diluent disclosed in the present disclosure may be polyethylene glycol 300, polyethylene glycol 600, polyethylene glycol 800, polyethylene glycol 1000, polyethylene glycol 2000, polyethylene glycol 4000, 1,4-butanediol, ethanol, isopropyl alcohol, glycerol, or 1-hexanol.

[0042] The ultraviolet (UV) absorbers disclosed in the present disclosure include 2,4-dihydroxybenzophenone (BP1), 2-[3-(2H-benzotriazol-2-yl)-4-hydroxyphenyl]ethyl methacrylate, 4-methacryloxy-2-hydroxybenzophenone, 2-phenylethyl acrylate, and 2-phenylethyl methacrylate. 2-(2'-hydroxy-5'-methacryloxyethylphenyl)-2H-benzotriazole; or 2-(4-benzoyl-3-hydroxyphenoxy)ethyl acrylate.

[0043] The blue light absorber disclosed in the present disclosure may be 4-(phenyldiazenyl)phenyl methacrylate.

[0044] The pigments disclosed in the present disclosure may include anthocyanins, beta-carotene, curcumin, luciferin, lutein, lycopene, phycobillin, phycoerythrim, phycocyanin, riboflavin (vitamin B2), zeaxanthin, photochromic dyes, thermochromic dyes, and derivatives thereof.

[0045] The contact lens composition materials disclosed herein are divided into hydrogels and silicone hydrogels. The hydrogels may be contact lens materials classified as Group 1 by the U.S. Food and Drug Administration, i.e., nonionic polymers with a low water content (less than 50 weight percent), such as Helfilcon A&B, Hioxifilcon B, Mafilcon, Polymacon, Tefilcon, and Tetrafilcon A. Alternatively, the hydrogels may be contact lens materials classified as Group 2 by the U.S. Food and Drug Administration, i.e., nonionic polymers with a high water content (greater than 50 weight percent), such as Acofilcon A, Alfafilcon A, Hilafilcon B, Hioxifilcon A, Hioxifilcon B, Hioxifilcon D, Nelfilcon A, Nesofilcon A, Omafilcon A, and Samfilcon A. Alternatively, the hydrogel may be a contact lens material classified by the U.S. Food and Drug Administration as Group 3, i.e., an ionic polymer with a low water content (less than 50 weight percent), such as Deltafilcon A. Alternatively, the hydrogel may be a contact lens material classified by the U.S. Food and Drug Administration as Group 4, i.e., an ionic polymer with a high water content (greater than 50 weight percent), such as Etafilcon A, Focofilcon A, Methafilcon A, Methafilcon B, Ocufilcon A, Ocufilcon B, Ocufilcon C, Ocufilcon D, Ocufilcon E, Phemfilcon A, or Vifilcon A.The silicone hydrogel may be a contact lens material classified as Group 5 by the U.S. Food and Drug Administration, such as Balafilcon A, Comfilcon A, Efrofilcon A, Enfilcon A, Galyfilcon A, Lotrafilcon A, Lotrafilcon B, Narafilcon A, Narafilcon B, Senofilcon A, Delefilcon A, or Somofilcon A.

[0046] The average transmittance of a contact lens composition disclosed herein is the average value of the transmittance at integer wavelengths in 1-nm increments. The average transmittance at 400 nm to 700 nm is the average value of the transmittance at wavelengths in 1-nm increments from 400 nm to 700 nm, i.e., the average value of the transmittance at 400 nm, 401 nm, 402 nm, 403 nm, to 700 nm. The average transmittance at 450 nm to 630 nm is the average value of the transmittance at wavelengths in 1-nm increments from 450 nm to 630 nm, i.e., the average value of the transmittance at 450 nm, 451 nm, 452 nm, 453 nm, to 630 nm. If the contact lens composition is a contact lens formulation solution, 1-2 μl or 1-2 ml is sampled and tested according to the device requirements. If the contact lens composition is a contact lens, testing is performed at the center of gravity of the contact lens when laid flat.

[0047] The various technical features of the contact lens composition of the present disclosure can be combined and configured to achieve corresponding effects.

[0048] Another embodiment of the present disclosure provides a contact lens product comprising the contact lens composition described above and a buffer solution in which the contact lens composition is immersed.

[0049] The contact lens structure disclosed in the present disclosure may be a single-layer lens or at least a two-layer lens. A color contact lens may be composed of two layers, such as a lens body layer and a color layer. A color contact lens may be composed of three layers, such as a lens body layer, a color layer, and a protective layer to prevent shedding. A color contact lens may be composed of four layers, such as a lens body layer, a first color layer, a second color layer, and a protective layer to prevent shedding. A color contact lens may be composed of five layers, such as a lens body layer, a first color layer, a second color layer, a third color layer, and a protective layer to prevent shedding. A color contact lens may be composed of another five layers, such as a lens body layer, a first color layer, a separation layer, a second color layer, and a protective layer to prevent shedding.

[0050] The stable structure of the contact lens disclosed in the present disclosure can have a rotational stability design such as a bottom thick vertical weight design, a double thick balanced design, an asymmetric balanced design, or an upper and lower thin stable design.

[0051] The contact lenses disclosed in the present disclosure may have functions such as myopia correction, hyperopia correction, presbyopia correction, astigmatism correction, myopia control, and orthokeratology (corneal reshaping).

[0052] The contact lens product disclosed herein comprises a contact lens composition, a buffer solution, and packaging, and the contact lens composition is immersed in the buffer solution. The contact lens composition and buffer solution may contain antibacterial agents, dispersants, moisturizing agents, beneficial agents, antioxidants, myopia control agents, surfactants, cooling agents, eye protection ingredients, buffers, chelating agents, diluents, UV absorbers, blue light absorbers, or dyes. The packaging can be manufactured by combining a plastic container with an aluminum foil cover. The plastic container can be made of polypropylene (PP), polystyrene (PS), polyethylene terephthalate (PET), or other plastic materials, or biodegradable plastics including polylactic acid (PLA), polyhydroxyalkanoates (PHA), or other biodegradable plastics. The biodegradable plastics can be mixed with biodegradable plasticizers to achieve a modified or altered effect. The aluminum foil cover disclosed in the present disclosure can be a composite aluminum foil material coated with a plastic.

[0053] The antibacterial efficacy described herein refers to the ability to resist bacterial growth or kill bacteria. The antibacterial efficacy test was designed with reference to ASTM E 2149-20 and included the following steps: (1) preparing a 5 cm x 5 cm film weighing approximately 1.05 g using the component ratios of the contact lens composition; (2) sterilizing the film with UV light; (3) immersing the film in 50 ml of sterile water for 24 hours; (4) removing the film, ensuring that it was not dripping, and cutting it into several pieces and placing them in an Erlenmeyer flask; (5) adding 50 ml of bacterial solution and co-cultivating the cut film and the Erlenmeyer flask for 24 hours, where the bacterial solution is Escherichia coli (ATCC 25922); and (6) diluting the bacterial solution in the Erlenmeyer flask appropriately and applying it to a medium suitable for bacterial growth, followed by incubation at 35°C for 24 hours. The formula for calculating antibacterial efficacy is (ba) / b x 100%, where CFU = Colony Forming Unit, b is the amount of bacteria cultured in the bacterial solution alone, and a is the amount of bacteria co-cultured in the bacterial solution and film. If the antibacterial efficacy is >50%, the component has antibacterial effect, and the higher the percentage of antibacterial efficacy, the greater the antibacterial effect. All other conditions comply with ASTM E 2149-20.

[0054] Unless otherwise specified, the measurement environment described in this disclosure is a temperature of 25°C and humidity of 50%.

[0055] According to the above embodiment, specific examples will be proposed and explained in detail below.

[0056] <First Comparative Example> The contact lens composition of Comparative Example 1 is a contact lens formulation solution that forms a contact lens after curing.

[0057] The contact lens composition of Comparative Example 1 contains a dispersant but does not contain an antibacterial agent or a moisturizing agent. The dispersant in Comparative Example 1 is polyvinylpyrrolidone. The components and proportions of each component in the contact lens composition of Comparative Example 1 are shown in Table 1.

[0058] [Table 1]

[0059] In Table 1, Pag is the percentage of nanosilver in the contact lens composition, Pd is the percentage of dispersant in the contact lens composition, Pm is the percentage of moisturizer in the contact lens composition, Dag is the particle size of nanosilver, Dc is the particle size of the contact lens composition, MWd is the molecular weight of the dispersant, Kd is the K value of the dispersant, and T4070 is the average transmittance of the contact lens composition from 400 nm to 700 nm. Also, in Table 1, "-" indicates that no test data is available.

[0060] As can be seen from Table 1, the contact lens composition of Comparative Example 1 had no antibacterial effect even after being cured into a contact lens.

[0061] If the parameter definitions in the following comparative examples and examples are the same as those in Table 1, they will not be further explained.

[0062] <Second Comparative Example> The contact lens composition of the second comparative example is a contact lens formulation solution that forms a contact lens after curing.

[0063] The contact lens composition of Comparative Example 2 contains an antibacterial agent but does not contain a dispersant or a humectant. The antibacterial agent of Comparative Example 2 is nanosilver. The components and proportions of each component of the contact lens composition of Comparative Example 2 are shown in Table 2.

[0064] [Table 2]

[0065] As can be seen from Table 2, the contact lens composition of Comparative Example 2 has antibacterial effect after being cured into a contact lens, but the nanosilver was not uniformly dispersed.

[0066] <First Example> The first embodiment contact lens composition is a contact lens formulation solution that forms a contact lens after curing.

[0067] The contact lens composition of Example 1 contains an antibacterial agent and a dispersing agent, but does not contain a humectant. The antibacterial agent is nanosilver, and the dispersing agent is polyvinylpyrrolidone. The components and proportions of each component of the contact lens composition of Example 1 are shown in Table 3.

[0068] [Table 3]

[0069] As can be seen from Table 3, the nanosilver in the contact lens composition of Example 1 began to precipitate after standing for 21 days, and the nanosilver was uniformly dispersed after the contact lens composition was cured into a contact lens.

[0070] <Second Example> The contact lens composition of the second embodiment is a contact lens formulation solution that forms a contact lens after curing.

[0071] The contact lens composition of Example 2 contains an antibacterial agent and a dispersing agent, but does not contain a humectant. The antibacterial agent is nanosilver, and the dispersing agent is polyvinylpyrrolidone. The components and proportions of each component of the contact lens composition of Example 2 are shown in Table 4.

[0072] [Table 4]

[0073] As can be seen from Table 4, the nanosilver in the contact lens composition of Example 2 began to precipitate after standing for 28 days, and the nanosilver was uniformly dispersed after the contact lens composition was cured into a contact lens.

[0074] <Third Example> The contact lens composition of the third embodiment is a contact lens formulation solution that forms a contact lens after curing.

[0075] The contact lens composition of Example 3 includes an antibacterial agent, a dispersant, and a moisturizer, where the antibacterial agent is nanosilver, the dispersant is polyvinylpyrrolidone, and the moisturizer is glucan. The components and the proportions of each component of the contact lens composition of Example 3 are shown in Table 5.

[0076] [Table 5]

[0077] As can be seen from Table 5, the nanosilver in the contact lens composition of Example 3 began to precipitate after standing for 14 days, and the nanosilver was uniformly dispersed after the contact lens composition was cured into a contact lens.

[0078] <Fourth Example> The contact lens composition of the fourth embodiment is a contact lens formulation solution that forms a contact lens after curing.

[0079] The contact lens composition of Example 4 includes an antibacterial agent, a dispersing agent, and a humectant, where the antibacterial agent is nanosilver, the dispersing agent is polyvinylpyrrolidone, and the humectant is glucan. The components and the proportions of each component of the contact lens composition of Example 4 are shown in Table 6A.

[0080] [Table 6A]

[0081] As can be seen from Table 6A, the nanosilver in the contact lens composition of Example 4 began to precipitate after standing for 14 days, and the nanosilver was uniformly dispersed after the contact lens composition was cured into a contact lens.

[0082] Additionally, the contact lens composition of Example 4 was used to conduct an antibacterial efficacy test according to the steps described in the previous paragraph, and the results are shown in Table 6B.

[0083] [Table 6B]

[0084] <Fifth Example> The contact lens composition of the fifth embodiment is a contact lens formulation solution that forms a contact lens after curing.

[0085] The contact lens composition of Example 5 contains an antibacterial agent and a dispersing agent, but does not contain a humectant. The antibacterial agent is nanosilver, and the dispersing agent is polyvinylpyrrolidone. The components and proportions of each component of the contact lens composition of Example 5 are shown in Table 7.

[0086] [Table 7]

[0087] As can be seen from Table 7, the nanosilver in the contact lens composition of Example 5 began to precipitate after being left standing for more than 28 days, and the nanosilver was uniformly dispersed after the contact lens composition was hardened into a contact lens.

[0088] <Sixth Example> The contact lens composition of the sixth embodiment is a contact lens formulation solution that forms a contact lens after curing.

[0089] The contact lens composition of Example 6 contains an antibacterial agent and a dispersing agent, but does not contain a humectant. The antibacterial agent is nanosilver, and the dispersing agent is polyvinylpyrrolidone. The components and proportions of each component of the contact lens composition of Example 6 are shown in Table 8.

[0090] [Table 8]

[0091] As can be seen from Table 8, the nanosilver in the contact lens composition of Example 6 began to precipitate after being left standing for more than 28 days, and the nanosilver was uniformly dispersed after the contact lens composition was hardened into a contact lens.

[0092] <Seventh Example> The seventh embodiment contact lens composition is a contact lens formulation solution that forms a contact lens after curing.

[0093] The contact lens composition of Example 7 includes an antibacterial agent, a dispersant, and a moisturizer, where the antibacterial agent is nanosilver, the dispersant is polyvinylpyrrolidone, and the moisturizer is glucan. The components and the proportions of each component of the contact lens composition of Example 7 are shown in Table 9.

[0094] [Table 9]

[0095] As can be seen from Table 9, the nanosilver in the contact lens composition of Example 7 began to precipitate after standing for 18 days, and the nanosilver was uniformly dispersed after the contact lens composition was cured into a contact lens.

[0096] <Eighth Example> The contact lens composition of the eighth embodiment is a contact lens formulation solution that forms a contact lens after curing.

[0097] The contact lens composition of Example 8 includes an antibacterial agent, a dispersant, and a moisturizer, where the antibacterial agent is nanosilver, the dispersant is polyvinylpyrrolidone, and the moisturizer is glucan. The components and the proportions of each component of the contact lens composition of Example 8 are shown in Table 10.

[0098] [Table 10]

[0099] As can be seen from Table 10, the nanosilver in the contact lens composition of Example 8 began to precipitate after standing for 18 days, and the nanosilver was uniformly dispersed after the contact lens composition was cured into a contact lens.

[0100] <Ninth Example> The contact lens composition of the ninth embodiment is a contact lens formulation solution that forms a contact lens after curing.

[0101] The contact lens composition of Example 9 contains an antibacterial agent and a dispersing agent, but does not contain a humectant. The antibacterial agent is nanosilver, and the dispersing agent is polyvinylpyrrolidone. The components and proportions of each component of the contact lens composition of Example 9 are shown in Table 11.

[0102] [Table 11]

[0103] As can be seen from Table 11, the nanosilver in the contact lens composition of Example 9 began to precipitate after the standing time was greater than 28 days, and the nanosilver was uniformly dispersed after the contact lens composition was cured into a contact lens.

[0104] <Tenth Example> The contact lens composition of the tenth embodiment is a contact lens formulation solution that forms a contact lens after curing.

[0105] The contact lens composition of Example 10 contains an antibacterial agent and a dispersing agent, but does not contain a humectant. The antibacterial agent is nanosilver, and the dispersing agent is polyvinylpyrrolidone. The components and proportions of each component of the contact lens composition of Example 10 are shown in Table 12.

[0106] [Table 12]

[0107] As can be seen from Table 12, the nanosilver in the contact lens composition of Example 10 began to precipitate after the standing time was greater than 28 days, and the nanosilver was uniformly dispersed after the contact lens composition was cured into a contact lens.

[0108] Although the present disclosure has been disclosed in the above embodiments, the present disclosure is not intended to be limited thereto, and any person skilled in the art can make various changes and modifications without departing from the spirit and scope of the present disclosure. Therefore, the scope of protection of the present disclosure is as defined by the claims attached below.

Claims

1. 1. A contact lens composition comprising: an antibacterial agent that is nanosilver; a dispersant that is a polymeric dispersant; Including, If the percentage of the nanosilver in the contact lens composition is Pg, the percentage of the dispersant in the contact lens composition is Pd, and the molecular weight of the dispersant is MWd, then: Pag / Pd≦0.001, and A contact lens composition that satisfies the condition 100,000 g / mol≦MWd.

2. 2. The contact lens composition according to claim 1, wherein the molecular weight of the dispersant is MWd, and the condition 1,000,000 g / mol≦MWd is satisfied.

3. 3. The contact lens composition of claim 2, wherein the polymeric dispersant is polyvinylpyrrolidone.

4. 2. The contact lens composition according to claim 1, which satisfies the condition: 0.0002≦Pag / Pd≦0.0007.

5. 2. The contact lens composition of claim 1, wherein the condition 0.0003%≦Pag is satisfied.

6. 2. The contact lens composition according to claim 1, wherein the condition 0.3%≦Pd≦3.0% is satisfied.

7. 2. The contact lens composition according to claim 1, wherein the particle size of the nanosilver is represented by Dag, and the particle size satisfies the condition Dag≦100 nm.

8. 2. The contact lens composition according to claim 1, wherein the particle diameter of the contact lens composition is represented by Dc, and the condition is satisfied: 100 nm≦Dc≦300 nm.

9. 2. The contact lens composition according to claim 1, wherein the K value of the dispersant is Kd, and the condition Kd satisfies 50≦Kd.

10. 2. The contact lens composition according to claim 1, wherein the average transmittance of said contact lens composition in the wavelength range of 400 nm to 700 nm, T4070, satisfies the condition 90%≦T4070.

11. The contact lens composition of claim 1; a buffer solution in which the contact lens composition is immersed; Contact lens products, including:

12. 1. A contact lens composition comprising: an antibacterial agent that is nanosilver; A moisturizer that is glucan, a dispersant that is a polymeric dispersant; Including, A contact lens composition that satisfies the condition 300,000 g / mol≦MWd, where MWd is the molecular weight of the dispersant.

13. 13. The contact lens composition of claim 12, wherein the condition 500,000 g / mol≦MWd is satisfied.

14. 14. The contact lens composition of claim 13, wherein the proportion of the nanosilver in the contact lens composition is Pag and the proportion of the dispersant in the contact lens composition is Pd, and the condition Pg / Pd≦0.0008 is satisfied.

15. 15. The contact lens composition of claim 14, wherein the condition 0.00025%≦Pag is satisfied.

16. 16. The contact lens composition of claim 15, wherein the condition 0.1%≦Pd is satisfied.

17. 17. The contact lens composition according to claim 16, wherein the particle size of the nanosilver is represented by Dag, and the condition Dag≦200 nm is satisfied.

18. 18. The contact lens composition of claim 17, wherein the polymeric dispersant is polyvinylpyrrolidone.

19. 19. The contact lens composition according to claim 18, wherein the proportion of the humectant in the contact lens composition is Pm, and the proportion satisfies the condition 0.5%≦Pm≦2.5%.

20. 20. The contact lens composition according to claim 19, wherein the K value of the dispersant is Kd, and the condition Kd satisfies 30≦Kd.

21. 21. The contact lens composition according to claim 20, wherein the particle size of the contact lens composition is Dc, and the condition Dc≦500 nm is satisfied.

22. 22. The contact lens composition according to claim 21, wherein the average transmittance of the contact lens composition in the wavelength range of 400 nm to 700 nm, T4070, satisfies the condition 85%≦T4070.

23. If the percentage of the nanosilver in the contact lens composition is Pag, the percentage of the dispersant in the contact lens composition is Pd, the percentage of the humectant in the contact lens composition is Pm, the particle size of the nanosilver is Dag, and the molecular weight of the dispersant is MWd, then Kd is the K value of the dispersant, and T4070 is the average transmittance of the contact lens composition in the range of 400 nm to 700 nm: 0.00042%≦Pag≦0.00048%, 0.8%≦Pd≦1.5%, 1.4%≦Pm≦1.6%, 0.0004≦Pag / Pd≦0.0005, 70 nm ≦ Dag ≦ 80 nm, 1200000g / mol≦MWd≦1300000g / mol, 85≦Kd≦95, and 13. The contact lens composition according to claim 12, which satisfies the condition 93%≦T4070≦100%.

24. The contact lens composition of claim 12; a buffer solution in which the contact lens composition is immersed; Contact lens products, including:

Images